Third, analysis of public ovarian cancer genomic data from the Gene Expression Omnibus (GEO) database demonstrated that TOP2A, TP53, GPX4, and SLC7A11 exhibit differential expression between cisplatin-resistant and cisplatin-sensitive OC cohorts. This evidence concerns the gene TOP2A and ovarian cancer.